Stroke is a major cause of death and disability and its incidence increases linearly with age and the level of systolic and diastolic blood pressure. Stroke, besides being a cause of long-term disability for the affected person, also imposes a significant burden on society and healthcare costs. Although good blood pressure control is very critical for stroke prevention, angiotensin receptor blockers (ARBs) may be superior to angiotensin-converting enzyme inhibitors (ACEIs) for the same degree of blood pressure control. This hypothesis has clinical and experimental support. ARBs prevent stroke incidence by blocking the angiotensin II (AII), AT 1 receptors preventing brain ischaemia and allowing AII to stimulate the unoccupied AT 2 receptors, which improve brain ischaemia. ACEIs, by reducing AII generation, are less effective in preventing stroke. This hypothesis provides evidence that AII plays an important role in the prevention of stroke. Certain ARBs like losartan, and telmisartan, irbesartan and candesartan possess additional properties which may play a role in stroke prevention, which is independent of AII. These include antiplatelet aggregating, hypouricemic, antidiabetic and atrial antifibrillatory effects. However, the most critical factor in stroke prevention is good blood pressure control irrespective of drug used.
Introduction
Stroke is a major cause of death and disability, and its incidence increases linearly with advancing age and level of blood pressure.
1,2 Lewington et al 2 have shown that the incidence of stroke is directly related to the level of systolic and diastolic blood pressure (SBP and DBP) for all age groups, but with higher prevalence in older than younger subjects. Stroke, besides being a cause of long-term disability for the affected person, is also a significant burden on society and healthcare expenditures. [3] [4] [5] Stroke ranks as the third leading cause of death in the United States and accounts for 700 000 incident strokes annually and 4.4 million stroke survivors, 5, 6 with direct and indirect cost estimates for 2005 of $56.8 billion. 7 The estimated expenditures for all cardiovascular diseases in the United States for 2005 are depicted in Figure 1 . Disability from stroke accounts for significant healthcare expenditures in the European Union as well, and these expenditures are also projected to rise in the future, since the incidence of stroke will increase with the aging of the population. 8 In an analysis of 11 major randomized intervention trials for the treatment of hypertension, stroke emerged as more common than myocardial infarction among hypertensive patients. 9 Possible causes for this increase in stroke are the ageing of the population and the poor control of hypertension. 1, 2 Whether the choice of drugs for the treatment of hypertension could play a role is debatable at present. Recently, it has been reported that drugs that impair the production of angiotensin II (AII), such as angiotensin-converting enzyme inhibitors (ACEIs) and beta blockers, are less effective in preventing strokes than drugs that stimulate AII production, such as diuretics, calcium channel blockers and angiotensin receptor blockers (ARBs). 10, 11 In this concise review, the role of antihypertensive drugs on stroke prevention as it relates to their inhibitory or stimulatory action on AII release will be discussed, and clinical and experimental evidence will be presented that ACEIs are less effective in stroke prevention than ARBs. Additionally, evidence will be presented about non-AII-mediated mechanisms for cerebroprotection by ARBs.
Mechanism of action of ACEIs and ARBs
AII is produced by the classical pathway through the action of the angiotensin-converting enzyme (ACE) and by the alternate pathway through the action of other enzymes, especially chymase ( Figure 2 ). After its generation, AII exerts its effects on peripheral vasoconstriction, aldosterone secretion, water retention, sympathetic nervous system stimulation and cardiovascular remodelling through attachment and stimulation of the AT 1 receptors. Simultaneously, it attaches itself and stimulates the AT 2 receptors, which have the opposite effect of the AT 1 receptors (Table 1) . ACEIs exert their blood pressure-lowering and antiremodelling effects through interference with the generation of AII by blocking the action of ACE, and possibly through prevention of degradation of bradykinin, a potent vasodilator, by blocking the action of kinase II, which is the same enzyme as the ACE (Figure 2 ). On the other hand, ARBs exert their beneficial effects on blood pressure-lowering, cardiovascular remodelling and stroke prevention by selectively blocking the AT 1 receptors and allowing the AII to stimulate the unoccupied AT 2 receptors. This dual effect of ARBs may be the cause of their superiority over the ACEIs in stroke prevention, as will be discussed later. In addition, experimental evidence indicates that blockage of the AT 1 receptors leads to the upregulation of the AT 2 receptors in endothelial cells through a complex mechanism of cross regulation between the AT 1 and AT 2 receptors, 12 which may enhance the stroke preventive effects of ARBs.
Clinical and experimental evidence
ACEIs and stroke incidence The hypothesis that AII might have a cerebroprotective effect was first advanced by Brown and Brown 13 in 1986 based on the results of the first Medical Research Council (MRC) study, 14 where the diuretic bendrofluazide reduced the incidence of strokes by 70% vs a 27% reduction by propranolol, both compared to placebo, for a similar decrease in blood pressure. They proposed that the increased production of AII by the diuretic constricted the proximal cerebral arteries and prevented the rupture of the Charcot-Bouchard micro-aneurysms and the development of cerebral haemorrhage. Their original observations were duplicated by a subsequent MRC study in elderly hypertensives, where the administration of hydrochlorothiazide/amiloride resulted in 33% stroke reduction vs 18% by atenolol compared to placebo for a similar decrease in blood pressure by both active drugs. 15 Similar results have been reported by other clinical trials using diuretics 16, 17 or calcium channel blockers. 18, 19 Contrary to the above presented results are the findings from randomized clinical trials using ACEIs. In the Perindopril Protection Against Recurrent Stroke Study (PROGRESS), the initial treatment of poststroke hypertensive patients with the ACEI perindopril, resulted in a meager 5% stroke reduction for a 5 mmHg decrease in SBP, compared to 43% stroke reduction, when the diuretic indapamide was added to the ACEI, for an additional SBP decrease of 7 mmHg. 20 The expected stroke reduction would have been 28%. A similar 5 mmHg decrease in SBP by indapamide in the Post-Stroke Antihypertensive Treatment Study (PATS) resulted in a 29% reduction of strokes. 21 In the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT) study, treatment of hypertensive patients with the ACEI lisinopril resulted in 15% higher incidence of strokes in the study population and in 40% higher incidence of strokes in black subjects, compared to the diuretic chlorthalidone. 17 It should be stressed, however, that the high incidence of strokes in black subjects by lisinopril was partly due to the poorer control of SBP, which was higher by 4 mmHg. Corroborating and enhancing these results are the findings from the Captopril Prevention Project (CAPP), where treatment of hypertensive patients with captopril showed a 43% higher incidence of strokes compared to conventional treatment. 22 This should be somewhat mitigated by the 3 mmHg higher SBP in the captopril group. The results on stroke incidence were equivocal in the second Australian National Blood Pressure study (ANBP2) where elderly hypertensive patients treated with the ACEI enalapril showed a 9% higher incidence of fatal strokes, and a 7% lower incidence of nonfatal strokes compared to hydrochlorothiazide. 23 In a recently published, randomized doubleblind, placebo controlled study of type II patients with DIABetes, HYpertension, microalbuminuria or proteinuriea, CArdiovascular events and Ramipril (DIABHYCAR), treatment with low-dose ramipril (1.25 mg/day) did not result in any significant decrease in the incidence of strokes compared to placebo, although it decreased the blood pressure by 2.43/1.06 mmHg and normalized microalbuminuria and proteinuria. 24 A 2 mmHg SBP decrease is usually associated with a 10% reduction in strokes. 25 Different findings from the above studies were reported from the Heart Outcomes Prevention Evaluation (HOPE) study, 26 which showed a 32% reduction in stroke incidence in patients treated with the ACEI ramipril compared to placebo. However, this study used higher doses of ramipril (10 mg/day) and included mostly normotensive, high-risk patients with pre-existing coronary artery disease, peripheral vascular disease and diabetes where the ACEIs are quite effective, more so when these results are compared to placebo-treated patients. Besides, the risk of stroke has been shown to be higher in patients with pre-existing coronary artery disease in whom prevention of myocardial infarction is associated with stroke prevention. 27 These studies are summarized in Table 2 .
ARBs and stroke incidence
Recently, several large clinical trials have shown that treatment of high-risk hypertensive patients with ARBs results in significant reduction of strokes. The Losartan Intervention For Endpoint reduction (LIFE) study, 28 showed that severely hypertensive patients with left ventricular hypertrophy (LVH) treated with a losartan-based regimen, had a 25% reduction in strokes compared to those treated with an atenolol-based regimen for the same decrease of blood pressure. A substudy of LIFE of patients with isolated systolic hypertension and LVH, treatment with the losartan-based regimen, resulted in a 40% stroke reduction compared to those treated with the atenolol-based regimen. 29 Complementary results to the LIFE study were subsequently reported from the Study on Cognition and Prognosis in the Elderly (SCOPE) study. 30 In this study, older patients with predominantly systolic hypertension, treated with a candesartan-based regimen, had a 27.8% reduction in nonfatal strokes and a 23.6% reduction in total strokes, compared Clinical and experimental evidence of stroke prevention SG Chrysant with patients treated with conventional antihypertensive drugs for similar control of blood pressure. In this study, the group that was treated with conventional drugs received placebo for the first 3 months. In a substudy of the SCOPE trial of older patients with isolated systolic hypertension, treatment with the candesartan-based regimen resulted in a 40% stroke reduction compared with those patients treated with conventional antihypertensive drugs. 31 In addition, candesartan has been demonstrated to provide secondary protection in patients who have suffered a previous stroke. In the Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) pilot study, 32 treatment of hypertensive patients with a previous stroke, with candesartan for 12 months, resulted in reduction of cumulative mortality and number of strokes by 52% compared to placebo treatment. This study was terminated prematurely due to the great disparity in outcomes between the two treatment arms, although there was no difference in SBP and DBP between the two treatment groups for the 12-month treatment period. Another small study in 24 poststroke hypertensive patients, without occlusive carotid disease, showed that administration of losartan 25-50 mg, 2-7 days after an ischaemic stroke, or transient ischaemic attack did not cause any significant changes in cerebral blood flow autoregulation, or result in any serious side effects despite a decrease in mean arterial pressure by 18.1 mmHg. 33 The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study 34 in high-risk hypertensive patients treated with either valsartan or amlodipine showed mixed results with respect to stroke prevention. Although this study was designed as a superiority study of valsartan against amlodipine for the same reduction of blood pressure, the results were mixed. In the first 6 months of treatment, the stroke incidence was 50% higher in the valsartan-treated group compared to amlodipine-treated patients. However, during this period, the blood pressure of the valsartan-treated group was higher by 4.0/ 2.1 mmHg compared to amlodipine-treated group. As the study progressed and the difference in blood pressure narrowed, the stroke incidence decreased and by the end of the study it was 25% lower in the valsartan-treated group compared to amlodipine-treated group despite the fact that the blood pressure was 1.8/1.5 mmHg higher in the valsartan-treated group. Therefore, the superiority hypothesis for valsartan would have been true if valsartan would have reduced the blood pressure to the same degree with amlodipine throughout the study. Perhaps the administered dose of valsartan 160 mg/day was not sufficient and if a dose of 320 mg/day, as is currently approved by the FDA for the treatment of hypertension, was given, the results might have been different. The recently published Morbidity and mortality after Stroke, Eprosartan Study (MOSES), provides additional evidence for superior stroke protection by ARBs. 35 This study compared the stroke protective effects of eprosartan vs nitrendipine in poststroke hypertensive patients. After 2.5 years of follow-up, eprosartan decreased the incidence of recurrent stroke by 25% compared to nitrendipine for the same reduction of blood pressure. These studies are listed in Table 2 . Corroborating evidence for better stroke protection by ARBs is also provided by the recently published meta-analysis by the Blood Pressure Lowering Treatment Trialists (BPLTC), which showed that ARBs are better than ACEIs in stroke prevention for equal blood pressure reductions. Valsartan decreased stroke by the end of study, but the overall stroke incidence was 15% higher.
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Experimental evidence supporting a possible unique role of AII and ARBs in stroke prevention
AII-mediated effects of ARBs
Subsequent to the original hypothesis by Brown and Brown 13 that AII could play a role in stroke prevention, several experimental studies have provided support for this hypothesis. [36] [37] [38] Fernandez et al 36 showed that AII exerted a protective role against acute vascular ischaemia and transitory paralysis of the hind limbs of the rat by applying an aortic ligature between the kidneys, thus rendering the left kidney ischaemic and producing renovascular hypertension. Removal of the ischaemic kidney reduced the level of plasma rennin activity and blood pressure to within normal values, but the limb's ischaemia persisted for 24 h. Exogenous administration of AII increased the blood pressure and restored the limb ischaemia by increasing the blood flow to the muscles of the hind limb. They concluded that the increased AII levels through renal ischaemia restored blood flow to the hind limb of the rat by stimulating the development of collateral circulation, an effect that was independent of its hypertensive action. In subsequent studies, Fernandez et al 37 demonstrated that exogenous AII infusion decreased the mortality of gerbils after unilateral carotid occlusion. In these studies, gerbils were subjected to cerebral ischaemia by unilateral carotid ligation. Immediately postligation, some gerbils were infused with AII 50, 250 and 500 mg/kg/min, whereas other gerbils were infused with either equipressor doses of metaraminol or normal saline. The AII infusion resulted in a dosedependent decrease in mortality of the gerbils, whereas the infusion of metaraminol or normal saline had no effect on mortality. The authors postulated that the beneficial effects of AII on cerebral ischaemia were independent of blood pressure and possibly due to the enhancement of pre-existing collateral circulation and reduction of cerebral ischaemia. In studies performed later, Fernandez et al 38 showed that the protective effects of AII on the brain ischaemia of gerbils was mediated through stimulation of the AT 2 receptors. Brain ischaemic gerbils pretreated with either the selective AT 1 receptor blocker losartan, or the selective AT 2 receptor agonist PD-123319, had decreased mortality compared to gerbils pretreated with normal saline or the ACEI enalapril. Additionally, pretreatment of these animals with enalapril neutralized the brain protective effects of losartan. These experiments reinforced the hypothesis that AII exerts its cerebroprotective effects through AT 2 receptor stimulation and this effect is enhanced by selective blockade of the AT 1 receptors. Findings supporting the above hypothesis were reported by Dai et al 39 in normotensive Wistar rats. Intracerebral administration of low-dose irbesartan that blocked the cerebral but not the systemic AT 1 receptors for 5 days prior to induction of focal brain ischaemia by occlusion of the middle cerebral artery for 90 min, improved the neurologic outcome of these rats in comparison to vehicle-treated rats. These experiments were reproduced and further extended by Dalmay et al 40 in gerbils. These investigators induced acute cerebral ischaemia in anaesthetized adult gerbils by unilateral carotid ligation and tested the effect of treatment 2 h postligation with two different ARBs (losartan 50 mg/kg, candesartan 1 mg/kg), two different ACEIs (enalapril 10 mg/kg, lisinopril 1 mg/kg) or their combination against a vehicle. They observed that the 3-day mortality of gerbils was not significantly decreased with the two ACEIs or their combination with the two ARBs compared to vehicle-treated gerbils. In contrast, the 3-day mortality of gerbils treated with either ARB was significantly decreased compared to controls. In other studies, administration of losartan in high or low doses in spontaneously hypertensive strokeprone rats (SHR-SP) has been shown to have a cerebroprotective effect independent of its blood pressure-lowering effect. 41, 42 Nonangiotensin-mediated cerebroprotective effects of ARBs Antidiabetic effects ARBs like ACEIs exert favourable effects on glucose metabolism and prevent new onset diabetes mellitus. 28, 34, 43 This effect is very important because diabetes mellitus increases greatly the cardiovascular and stroke consequences of hypertension.
5, 44 The beneficial effects of most ARBs on glucose metabolism and prevention of new onset diabetes mellitus have been attributed to their blockade of AII. Recent studies have suggested that AII may impair glucose metabolism through its adverse effects on insulin signalling pathways, tissue blood flow, oxidative stress, sympathetic activity and adipogenesis. [45] [46] [47] [48] However, certain ARBs like telmisartan exert their beneficial effects on glucose metabolism independently of the reninangiotensin system. 49 , 50 The molecule of telmisartan has a structural similarity to peroxisome proliferator-activated receptor-gamma (PPAR gamma) ligand pioglitazone, which has been approved for the treatment of type II diabetes mellitus. These drugs play an important role in regulating carbohydrate and lipid metabolism, by increasing insulin sensitivity. 49, 50 In studies in rats fed a high carbohydrate, high-fat diet, telmisartan given in doses similar to those used for the treatment of hypertension, reduced serum levels of glucose, insulin and triglycerides. 50 Antiplatelet effects Other ARBs, like losartan exert their stroke preventive effects through their antiplatelet aggregating effects. Increased platelet aggregation and high uric acid levels have been both associated with increased cardiovascular events and strokes. Platelet activation within the arterial lumen releases several substances including ADP, serotonin and thromboxane A 2 (TXA 2 ) and P-selectin, which all cause platelet aggregation. Recent experimental studies have shown that losartan interacts with the TXA 2 /PGH 2 receptor in human platelets and also platelet activation by the TXA 2 agonist U46619 was significantly inhibited by losartan dosedependently. 51 Losartan also blocks the action of P-selectin on platelet adhesion. P-selectin is an adhesion protein that is stored in the alpha granules of platelets, and platelets from SHR-SP have a higher expression of P-selectin and a higher ability to adhere to synthetic and endothelial surfaces than platelets from normotensive WKY rats. Treatment of platelets from these animals with losartan decreased their adhesiveness to surfaces, whereas treatment with candesartan or valsartan had no significant effect on platelet adhesiveness. 52 These studies indicated that the action of losartan on platelet adhesion was not mediated through the AT 1 receptor because neither the losartan's metabolite EXP 3174, nor the other ARBs, candesartan and valsartan were able to prevent platelet adhesion or significantly suppress the expression of P-selectin on platelet surface. The increased expression of P-selectin on the platelet surface of SHR-SP has been blamed for the increased thrombogenicity and the higher incidence of strokes seen in these animals. 53, 54 Hypouricaemic effects Another mechanism, also independent of RAAS, by which certain ARBs could prevent the incidence of strokes, is their effect on serum uric acid. Although the role of uric acid as a risk factor for cardiovascular diseases and strokes has been widely debated over the years, recent studies have provided fresh evidence that high serum uric acid levels could be related to a higher incidence of hypertension, 55, 56 cardiovascular diseases and strokes, especially in patients with preexisting hypertension, heart failure or diabetes mellitus. [57] [58] [59] [60] Hypertensive patients, particularly with hyperuricaemia have a higher risk of experiencing cardiovascular or cerebrovascular disease than patients with normal uric acid levels. [57] [58] [59] [60] Although the mechanism by which uric acid exerts its pathogenetic effect on cardiovascular and cerebrovascular complications is still unclear, high uric acid levels have been shown to induce inflammation, endothelial dysfunction, oxidative metabolism, and platelet adhesion and aggregation. [61] [62] [63] [64] [65] All these changes induced by high uric acid levels could conceivably lead to cardiovascular complications and stroke and therefore, drugs that lower uric acid levels have been shown to reverse these changes. [61] [62] [63] [64] [65] Losartan, in exception to other ARBs, lowers uric acid levels and its use for the treatment of hypertension has been shown to decrease the incidence of cardiovascular complications and strokes. 66, 67 In fact, the results from the LIFE study showed that the baseline uric acid level was significantly associated with cardiovascular complications and strokes, especially in women, and that its lowering with losartan accounted for 29% of the reduction of strokes compared to atenolol. 66 Atrial antifibrillatory effects Several recent studies have demonstrated that ARBs either decrease the recurrence of pre-existing atrial fibrillation (AF) after conversion to sinus rhythm, or prevent the new onset of AF. 68, 69 Administration of irbesartan 150-300 mg/day in combination with amiodarone 400 mg/day was administered to 79 patients after conversion of chronic AF to sinus rhythm and compared with 75 similar patients treated with amiodarone 400 mg/day. After a median observation time of 254 days, 79.52% of patients on irbesartan plus amiodarone and 55.91% of patients on amiodarone alone remained in sinus rhythm, 69 which was statistically significant (P ¼ 0.007). In a subanalysis of the LIFE study, 8851 patients of 9193 with hypertension and LVH did not have AF at baseline. During the 4.871 years of follow-up, 150 patients of 4298 randomized to the losartan treatment group developed new onset AF vs 221 patients of 4182 randomized to the atenolol treatment group, 69 which was statistically significant (P ¼ 0.001). This beneficial effect of losartan on new onset AF has been attributed to structural remodelling of the atria. Experimental studies in the dogs have also demonstrated that another ARB, candesartan, shortened the duration of experimentally induced AF, and reduced the interstitial fibrosis of the atria compared to the control group (Po0.001). These positive effects of candesartan were attributed to its suppression of structural atrial remodelling. 70 These beneficial effects of ARBs on AF could add to their stroke protective effects.
Discussion
Stroke is a major cause of death and disability, and a significant social and financial burden worldwide. [3] [4] [5] The incidence of stroke is directly related to blood pressure and age, 1, 2 and is expected to rise significantly in the future as the age of the population increases putting a great financial burden on society. 7 The direct and indirect costs of strokes in the US have been projected at $56.8 billion for 2005 and account for one-third of the total health expenditure (Figure 1) . Successful blood pressure control is the most critical factor in stroke prevention and is shared by all antihypertensive drugs, although certain drugs, such as diuretics, CCBs and ARBs, which stimulate AII production, may provide an additional benefit for the same blood pressure reduction, than drugs that suppress it, such as beta blockers and ACEIs. Several clinical and experimental studies presented earlier have provided evidence that AII can be cerebroprotective and its effects on ischaemic stroke are mediated through local stimulation of the AT 2 receptors. [36] [37] [38] [39] [40] Stimulation of AT 1 receptors in the brain by AII causes constriction of proximal arteries and could prevent the rupture of Charcot-Bouchard microaneurysms and the development of cerebral haemorrhage, as originally proposed by Brown and Brown. 13 It has been reported that AT 2 receptors are overexpressed in areas of injury in the brain and counteract the undesirable effects of AT 1 receptor stimulation by AII. This could also explain the observations of Brown and Brown 13 that drugs that stimulate AII production are stroke protective. However, drugs that selectively block the AT 1 receptors, such as the ARBs, have additional advantages over drugs that only stimulate AII production, since by blocking the AT 1 receptors, they upregulate the expression of AT 2 receptors 12 and thus, they allow the free AII to stimulate the unoccupied AT 2 receptors leading to improvement of local ischaemia through local vasodilation of pre-existing local collateral vessels. These are, perhaps, the reasons that losartan, candesartan and eprosartan have demonstrated a greater stroke reduction than other antihypertensive drugs 28, 30, 33 and especially in elderly patients with isolated systolic hypertension. 29, 31 Other mechanisms by which ARBs could reduce the incidence of new or recurrent stroke include the beneficial effects of some ARBs on blood glucose control by increasing insulin sensitivity, 49, 50 their platelet antiaggregating effects, [51] [52] [53] [54] their hypouricemic effects 66, 67 and their atrial antifibrillatory effects. [69] [70] [71] All these actions of ARBs could add to their AII-mediated stroke protective effects. However, these positive effects of ARBs on stroke protection should not by any means exclude the critical role of blood pressure control on stroke prevention, since the blood pressure levels (systolic and diastolic) have a continuous and direct effect on stroke incidence for all age groups. 1 However, selection of ARBs could provide an additional benefit in stroke reduction for the same degree of blood pressure decrease, as was clearly demonstrated in the LIFE, SCOPE and MOSES studies. [28] [29] [30] [31] 35 The results of the VALUE study are in agreement with this hypothesis. The early, higher incidence of stroke in the valsartan treatment group compared to the amlodipine treatment group was due to poor blood pressure control by valsartan. However, this higher stroke incidence decreased as the study progressed and the differences in blood pressure were narrowed, and by the end of the study, it was 25% lower in favour of valsartan even though the blood pressure in the valsartan treatment group was higher by 1.8/1.5 mmHg.
In conclusion, the clinical and experimental studies presented in this review raise a provocative hypothesis regarding the stroke prevention superiority of ARBs vs the ACEIs, which has not been confirmed yet, since there are no direct comparisons between these two classes of drugs. The recently published report of the blood pressure-lowering treatment trialists, 25 provides additional support for this concept. Head to head comparisons of ACEIs and ARBs will either confirm or nullify this concept.
The still ongoing ONTARGET study, 71 which compares the effects of the ARB telmisartan 80 mg/day, vs the ACEI ramipril 10 mg/day, vs their combination on cardiovascular outcomes in 23 400 high-risk hypertensive patients for 5 years, will, hopefully, provide the needed evidence in favour or against this hypothesis.
